Dialyzers Market Global Market Report 2024

A dialyzer is a medical device utilized for filtering waste chemicals and eliminating excess fluid from an individual's blood in cases where the kidneys are not functioning properly. It acts as a substitute for the kidneys by employing semipermeable membranes to separate compounds in solution through uneven diffusion. This process effectively filters pollutants from the bloodstream of patients with kidney malfunction.

The primary types of dialyzers are high-flux dialyzers and low-flux dialyzers. High-flux dialyzers feature larger holes, allowing them to remove larger molecules such as beta-2 microglobulin. These dialyzers can be categorized based on their usage as disposable or reusable and can be employed in various settings, including in-center dialysis, home dialysis, hospital dialysis, independent dialysis, peritoneal dialysis, and home hemodialysis.

The dialyzers market research report is one of a series of new reports that provides dialyzers market statistics, including dialyzers industry global market size, regional shares, competitors with a dialyzers market share, detailed dialyzers market segments, market trends and opportunities, and any further data you may need to thrive in the dialyzers industry. This dialyzers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dialyzers market size has grown strongly in recent years. It will grow from $3.95 billion in 2023 to $4.31 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth observed in the historical period in the dialyzer market can be attributed to various factors, including an aging population, advancements in healthcare infrastructure, increased investment in research and development, and a rise in the number of dialysis centers. These factors collectively contributed to the expansion and improvement of dialysis services and technologies.

The dialyzers market size is expected to see strong growth in the next few years. It will grow to $5.9 billion in 2028 at a compound annual growth rate (CAGR) of 8.2%. The anticipated growth in the forecast period for the dialyzer market can be attributed to various factors. These include the increasing prevalence of chronic kidney diseases, rising disposable income, a growing healthcare expenditure, and a rising demand for home dialysis treatment options. Noteworthy trends expected in the forecast period encompass the development of wearable dialysis devices, integration of artificial intelligence (AI) in dialysis technologies, remote monitoring capabilities, the adoption of value-based care models, and the emergence of bioengineered dialyzers.

The increasing prevalence of end-stage renal illness is anticipated to drive the expansion of the dialyzer market in the foreseeable future. End-stage renal failure (ESRF), also known as end-stage renal disease (ESRD), marks the irreversible culmination of chronic kidney disease, where kidney function deteriorates to the extent that the organs can no longer function independently. Dialyzers play a crucial role in the dialysis process for end-stage renal disease patients, effectively removing waste and excess fluid from the bloodstream and subsequently reintroducing filtered blood back into the patient's body. As of July 2022, the Centers for Disease Control and Prevention reported nearly 37 million people diagnosed with chronic kidney disease in the US, representing 15 percent of adults. Additionally, data from the Australian Institute of Health and Welfare in February 2023 indicated that 17,700 Australians died of chronic kidney disease in 2020, accounting for 11 percent of all deaths. The escalating incidence of end-stage renal illness underscores the growth trajectory of the dialyzer market.

The rising rates of diabetes and cardiovascular disease are poised to propel the dialyzer market's growth. Diabetes and cardiovascular disease pose significant health risks, with elevated blood sugar levels contributing to an increased likelihood of heart-related conditions. Patients afflicted with diabetes and cardiovascular disease utilize dialyzers to eliminate waste products and excess fluids from their bloodstream, managing complications and enhancing overall health by addressing potential kidney dysfunction and impaired filtration. According to the World Health Organization, chronic diseases account for 74% of global fatalities, with 41 million deaths annually, encompassing 17.9 million deaths from cardiovascular diseases, 9.3 million from cancer, 4.1 million from chronic respiratory diseases, and 2.0 million from diabetes. The mounting rates of diabetes and cardiovascular disease underscore the driving force behind the dialyzer market's expansion.

Leading companies in the dialyzer market are committed to innovation, focusing on the development of advanced products such as hemocompatible dialyzers to ensure reliable patient care. Hemocompatible dialyzers are designed to minimize the activation of the blood's clotting system and the inflammatory response, reducing the risk of complications during dialysis, including blood clots, bleeding, and infection. Fresenius Medical Care AG & Co. KGaA, a German-based dialyzer manufacturer, introduced the FX CorAL dialyzer in November 2021. Leveraging polysulfone, a unique material with superior filtration and hemocompatibility properties, the dialyzer's fibers feature a distinctive shape to ensure uniform dialysis fluid wash around each fiber, improving clearance. The lateral blood entry port reduces the risk of blood kinking during usage, promoting more homogeneous circulation and enhancing the safety of therapy. Additionally, the FX-class dialyzers are steam-sterilized and environmentally friendly due to their lightweight construction. This emphasis on innovation positions major market players to meet the evolving needs of patients and healthcare providers in the dialyzer market.

Leading companies in the dialyzer market are embracing a strategic partnership approach to elevate the quality of life and overall patient care experience for individuals grappling with end-stage renal disease (ESRD). Strategic partnerships involve collaborative efforts where companies synergize their strengths and resources, resulting in mutual benefits and shared success. An illustrative example of this approach is evident in the December 2021 partnership between Alio Inc., a US-based medtech company, and Lifeline Vascular Care, a US-based medical company. This strategic collaboration is geared towards enhancing the treatment options for ESRD patients. The partnership encompasses clinical trials aimed at validating the effectiveness of Alio's SmartPatch sensor technology, the procurement of Alio's remote monitoring system, and the implementation of value-based care arrangements. The overarching goal is to improve patient outcomes and simultaneously reduce care costs.

In another strategic move, B. Braun SE, a prominent Germany-based manufacturer of dialyzers, executed an acquisition in March 2022 by acquiring Intermedt Medizin & Technik GmbH for an undisclosed amount. This strategic acquisition positions B. Braun to fortify and expand its product portfolio by gaining access to the comprehensive range of dialysis products and services offered by Intermedt. As a Germany-based manufacturer specializing in dialyzers and dialysis concentrates, Intermedt Medizin & Technik GmbH becomes an integral component of B. Braun's strategic growth and development in the dialyzer market. Through such strategic initiatives, major companies in the dialyzer market are not only enhancing their product offerings but also leveraging collaborations and acquisitions to shape the future landscape of patient care in the realm of end-stage renal disease.

Major companies operating in the dialyzers market market include Merck & Co Inc., Thermo Fisher Scientific Inc., Medtronic PLC, Asahi Kasei Medical Co Ltd., Toray Medical Co Ltd., Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Nipro Corporation, Teleflex Incorporated, Nikkiso Co Ltd., Weigao group, Fresenius Medical Care AG & Co KGaA, Allmed Medical Products Co Ltd., NxStage Medical Inc., Cantel Medical Corporation, Medivators Inc., Jiangxi Sanxin Medical Technology Co Ltd., Rockwell Medical Inc., Xenios AG, SWS Hemodialysis Care Co Ltd., Kawasumi Laboratories Incorporated, Geno Technology Inc., Dialife SA, Triton Medical Services Pvt Ltd., Anhui Jinye Industrial Co Ltd., Haidylena, and Farmasol S.A

North America was the largest region in the dialyzers market in 2023. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Dialyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The dialyzer market consists of revenues earned by entities by providing services such as removal of excess fluid, filtering blood from waste products. The market value includes the value of related goods sold by the service provider or included within the service offering. The dialyzer market also consists of sales of tube-type dialyzers, flat-type dialyzers, and hollow fiber-type dialyzers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.